Parameter Identification for a Model of Neonatal Fc Receptor-Mediated Recycling of Endogenous Immunoglobulin G in Humans
暂无分享,去创建一个
[1] T. Waldmann,et al. Clinical and experimental metabolism of normal 6.6s gamma-globulin in normal subjects and in patients with macroglobulinemia and multiple myeloma. , 1963, The Journal of laboratory and clinical medicine.
[2] W Strober,et al. Metabolism of immunoglobulins. , 1969, Progress in allergy.
[3] R. Bellman,et al. On structural identifiability , 1970 .
[4] S. Shaughnessy,et al. Do No Harm: Health Systems’ Duty to Promote Clinician Well-Being , 2022, American Journal of Hospital Medicine.
[5] Monoclonal anti-cea antibody , 1982 .
[6] David H. Anderson. Compartmental Modeling and Tracer Kinetics , 1983 .
[7] T. Waldmann,et al. Familial hypercatabolic hypoproteinemia. A disorder of endogenous catabolism of albumin and immunoglobulin. , 1990, The Journal of clinical investigation.
[8] S. Huang,et al. The effects of measurement errors in the plasma radioactivity curve on parameter estimation in positron emission tomography. , 1991, Physics in medicine and biology.
[9] C. Anderson,et al. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[10] Rainer Storn,et al. Differential Evolution – A Simple and Efficient Heuristic for global Optimization over Continuous Spaces , 1997, J. Glob. Optim..
[11] Claudio Cobelli,et al. Tracer Kinetics In Biomedical Research , 2000 .
[12] R. Hansen,et al. Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia. , 2003, Journal of pharmaceutical sciences.
[13] Claudio Cobelli,et al. Generalized Sensitivity Functions in Physiological System Identification , 1999, Annals of Biomedical Engineering.
[14] Anna M. Wu,et al. A Predictive Model of Therapeutic Monoclonal Antibody Dynamics and Regulation by the Neonatal Fc Receptor (FcRn) , 2005, Annals of Biomedical Engineering.
[15] Jonghan Kim,et al. Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model. , 2007, Clinical immunology.
[16] Joseph P. Balthasar,et al. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice , 2007, Journal of Pharmacokinetics and Pharmacodynamics.
[17] W Wang,et al. Monoclonal Antibody Pharmacokinetics and Pharmacodynamics , 2008, Clinical pharmacology and therapeutics.
[18] Lanyan Fang,et al. Predictive Physiologically Based Pharmacokinetic Model for Antibody-Directed Enzyme Prodrug Therapy , 2008, Drug Metabolism and Disposition.
[19] Ursula Klingmüller,et al. Structural and practical identifiability analysis of partially observed dynamical models by exploiting the profile likelihood , 2009, Bioinform..
[20] John Hattersley,et al. Mathematical modelling of immune condition dynamics : a clinical perspective , 2009 .
[21] Joseph P Balthasar,et al. Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibody. , 2010, Journal of pharmaceutical sciences.
[22] E. J. Routh. A Treatise on the Stability of a Given State of Motion: Particularly Steady Motion , 2010 .
[23] Dhaval K. Shah,et al. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human , 2011, Journal of Pharmacokinetics and Pharmacodynamics.
[24] W. Krzyzanski,et al. Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor , 2012, Journal of Pharmacokinetics and Pharmacodynamics.
[25] F. Theil,et al. Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice , 2012, mAbs.
[26] Jim J. Xiao. Pharmacokinetic Models for FcRn-Mediated IgG Disposition , 2012, Journal of biomedicine & biotechnology.
[27] Evaluation of a Catenary PBPK Model for Predicting the In Vivo Disposition of mAbs Engineered for High-Affinity Binding to FcRn , 2012, The AAPS Journal.
[28] Neil D. Evans,et al. Describing the effectiveness of immunosuppression drugs and apheresis in the treatment of transplant patients , 2013, Comput. Methods Programs Biomed..
[29] S. Iyer,et al. Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[30] W. Huisinga,et al. Monoclonal antibody disposition: a simplified PBPK model and its implications for the derivation and interpretation of classical compartment models , 2014, Journal of Pharmacokinetics and Pharmacodynamics.
[31] Masoud Jamei,et al. Simulation of Monoclonal Antibody Pharmacokinetics in HumansUsing a Minimal Physiologically Based Model , 2014, The AAPS Journal.
[32] Subhojit Ghosh. A differential evolution based approach for estimating minimal model parameters from IVGTT data , 2014, Comput. Biol. Medicine.
[33] H. Goldschmidt,et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. , 2016, The Lancet. Oncology.
[34] F. Kappel,et al. Generalized sensitivity functions for multiple output systems , 2016 .
[35] A. Dispenzieri,et al. High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma , 2017, Blood Cancer Journal.
[36] M. Chappell,et al. Analysis of a Compartmental Model of Endogenous Immunoglobulin G Metabolism with Application to Multiple Myeloma , 2017, Front. Physiol..
[37] S. Lonial,et al. Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma , 2017, Clinical Pharmacokinetics.
[38] J. Lancet,et al. ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS , 2016, Blood Cancer Journal.